Role of serum Golgi protein 73 in nonalcoholic fatty liver disease

Hang ZHANG; Jinchun LIU

doi:10.3969/j.issn.1001-5256.2023.03.028

Volume 39 Issue 3

Mar. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(3): 657-662

PDF( 1767 KB)

Role of serum Golgi protein 73 in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.03.028

Hang ZHANG¹,
Jinchun LIU^{2
,
,
,}

1.
Graduate School of Shanxi Medical University, Taiyuan 030001, China
2.
Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, China

Research funding:

Shanxi Province Science and Technology Achievement Transformation Guidance Special Project (201904D131030)

More Information

Corresponding author: LIU Jinchun, zxr610624@163.com (ORCID: 0000-0002-1984-6802)
Received Date: 2022-07-06
Accepted Date: 2022-08-21
Published Date: 2023-03-20

Abstract

Abstract

Golgi protein 73 (GP73) is a Golgi transmembrane protein that can be released into blood by cleavage. An increasing number of studies have shown that the increase in serum GP73 is closely associated with the development and progression of nonalcoholic fatty liver disease (NAFLD) and serum GP73 is expected to be used as a potential serological marker for the diagnosis and assessment of NAFLD. This article reviews the research advances in serum GP73 in NAFLD and analyzes its potential mechanism of action, so as to provide new options for the therapeutic targets of NAFLD.
- Golgi Protein 73,
- Non-alcoholic Fatty Fiver Disease,
- Liver Cirrohosis,
- Serum Biomarker

FullText(HTML)

References(40)

References

[1]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3.
[2]	CHALASANI N, YOUNOSSI Z, LAVINE JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
[3]	ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904. DOI: 10.1016/j.jhep.2018.05.036.
[4]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7.
[5]	WANG BL, SUN YM, YOU H. The era of the reversal of liver fibrosis and cirrhosis: Current status and challenges[J]. J Clin Hepatol, 2019, 35(4): 705-708. DOI: 10.3969/j.issn.1001-5256.2019.04.001. 王冰琼, 孙亚朦, 尤红. 肝纤维化和肝硬化逆转的时代: 现状与挑战[J]. 临床肝胆病杂志, 2019, 35(4): 705-708. DOI: 10.3969/j.issn.1001-5256.2019.04.001.
[6]	WANG L, YAO M, LIU S, et al. Serum golgi protein 73 as a potential biomarker for hepatic necroinflammation in population with nonalcoholic steatohepatitis[J]. Dis Markers, 2020, 2020: 6036904. DOI: 10.1155/2020/6036904.
[7]	LI Y, YANG Y, LI Y, et al. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis[J]. J Int Med Res, 2021, 49(11): 3000605211055378. DOI: 10.1177/03000605211055378.
[8]	KLADNEY RD, BULLA GA, GUO L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene, 2000, 249(1-2): 53-65. DOI: 10.1016/s0378-1119(00)00136-0.
[9]	XIA Y, ZHANG Y, SHEN M, et al. Golgi protein 73 and its diagnostic value in liver diseases[J]. Cell Prolif, 2019, 52(2): e12538. DOI: 10.1111/cpr.12538.
[10]	KLADNEY RD, CUI X, BULLA GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J]. Hepatology, 2002, 35(6): 1431-1440. DOI: 10.1053/jhep.2002.32525.
[11]	IFTIKHAR R, KLADNEY RD, HAVLIOGLU N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol, 2004, 99(6): 1087-1095. DOI: 10.1111/j.1572-0241.2004.30572.x.
[12]	YAO MJ, WANG LJ, GUAN GW, et al. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. J Clin Hepatol, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012. 姚明解, 王雷婕, 关贵文, 等. 血清高尔基体蛋白73在辅助诊断慢性乙型肝炎患者中度以上肝损伤中的应用[J]. 临床肝胆病杂志, 2018, 34(4): 755-759. DOI: 10.3969/j.issn.1001-5256.2018.04.012.
[13]	MAO Y, YANG H, XU H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693. DOI: 10.1136/gut.2010.214916.
[14]	LIU Y, HU X, LIU S, et al. golgi phosphoprotein 73: The driver of epithelial-mesenchymal transition in cancer[J]. Front Oncol, 2021, 11: 783860. DOI: 10.3389/fonc.2021.783860.
[15]	DANG Y, YU J, ZHAO S, et al. GOLM1 drives colorectal cancer metastasis by regulating myeloid-derived suppressor cells[J]. J Cancer, 2021, 12(23): 7158-7166. DOI: 10.7150/jca.61567.
[16]	PU Y, SONG Y, ZHANG M, et al. GOLM1 restricts colitis and colon tumorigenesis by ensuring Notch signaling equilibrium in intestinal homeostasis[J]. Signal Transduct Target Ther, 2021, 6(1): 148. DOI: 10.1038/s41392-021-00535-1.
[17]	LIU X, WAN X, LU S, et al. Evaluation of a magnetic particles-based chemiluminescence enzyme immunoassay for Golgi protein 73 in human serum[J]. Clin Chim Acta, 2015, 445: 54-59. DOI: 10.1016/j.cca.2015.03.008.
[18]	WAIDELY E, AL-YUOBI AR, BASHAMMAKH AS, et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection[J]. Analyst, 2016, 141(1): 36-44. DOI: 10.1039/c5an01884f.
[19]	LIN S, SVOBODA KK, FENG JQ, et al. The biological function of type I receptors of bone morphogenetic protein in bone[J]. Bone Res, 2016, 4: 16005. DOI: 10.1038/boneres.2016.5.
[20]	ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
[21]	ZHENG KI, LIU WY, PAN XY, et al. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001174. DOI: 10.1136/bmjdrc-2020-001174.
[22]	FENG JY, ZHONG H. Lipid characteristics of fatty liver induced by overexpression of Golgi transmembrane glycoprotein 73[J]. Chin J Biotechnol, 2022, 38: 2322-2331. DOI: 10.13345/j.cjb.210808. 丰江岳, 钟辉. 高尔基体跨膜糖蛋白73高表达诱发脂肪肝的脂类特性分析[J]. 生物工程学报, 2022, 38: 2322-2331. DOI: 10.13345/j.cjb.210808.
[23]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[24]	VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
[25]	YAO M, WANG L, LEUNG P, et al. The clinical significance of GP73 in immunologically mediated chronic liver diseases: experimental data and literature review[J]. Clin Rev Allergy Immunol, 2018, 54(2): 282-294. DOI: 10.1007/s12016-017-8655-y.
[26]	XU Z, LIU L, PAN X, et al. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J]. Medicine (Baltimore), 2015, 94(12): e659. DOI: 10.1097/MD.0000000000000659.
[27]	LIU L, WANG J, FENG J, et al. Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease[J]. Sci Rep, 2018, 8(1): 16730. DOI: 10.1038/s41598-018-34714-y.
[28]	OOI GJ, BURTON PR, DOYLE L, et al. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese[J]. Obes Surg, 2017, 27(1): 115-125. DOI: 10.1007/s11695-016-2246-5.
[29]	LI S, HUANG P, JEYARAJAN AJ, et al. Assessment of non-invasive markers for the prediction of esophageal variceal hemorrhage[J]. Front Med (Lausanne), 2021, 8: 770836. DOI: 10.3389/fmed.2021.770836.
[30]	SHIMANO H, SATO R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13(12): 710-730. DOI: 10.1038/nrendo.2017.91.
[31]	YANG X, WU F, CHEN J, et al. GP73 regulates hepatic steatosis by enhancing SCAP-SREBPs interaction[J]. Sci Rep, 2017, 7(1): 14932. DOI: 10.1038/s41598-017-06500-9.
[32]	KAWAMURA S, MATSUSHITA Y, KUROSAKI S, et al. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis[J]. J Clin Invest, 2022, 132(11): e151895. DOI: 10.1172/JCI151895.
[33]	HIGASHI T, FRIEDMAN SL, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121: 27-42. DOI: 10.1016/j.addr.2017.05.007.
[34]	MA LY, ZHEN YN, LUO YP, et al. Expression and mechanism of gp73 in liver tissue of mouse liver fibrosis[J]. Basic Clin Med, 2020, 40(6), 771-776. DOI: 10.3969/j.issn.1001-6325.2020.06.008. 马玲玉, 甄一宁, 罗云萍, 等. gp73在小鼠肝纤维化肝组织中的表达及机制[J]. 基础医学与临床, 2020, 40(6): 771-776. DOI: 10.3969/j.issn.1001-6325.2020.06.008.
[35]	N ZEKRI AR, EL KASSAS M, SALAM E, et al. The possible role of Dickkopf-1, Golgi protein- 73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study[J]. Sci Rep, 2020, 10(1): 5156. DOI: 10.1038/s41598-020-62051-6.
[36]	WEI C, YANG X, LIU N, et al. Tumor microenvironment regulation by the endoplasmic reticulum stress transmission mediator Golgi protein 73 in mice[J]. Hepatology, 2019, 70(3): 851-870. DOI: 10.1002/hep.30549.
[37]	LEBEAUPIN C, VALLÉE D, HAZARI Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69(4): 927-947. DOI: 10.1016/j.jhep.2018.06.008.
[38]	TAKACS CN, ANDREO U, DAO THI VL, et al. Differential regulation of lipoprotein and hepatitis C virus secretion by rab1b[J]. Cell Rep, 2017, 21(2): 431-441. DOI: 10.1016/j.celrep.2017.09.053.
[39]	PENG Y, ZENG Q, WAN L, et al. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity[J]. Nat Commun, 2021, 12(1): 7004. DOI: 10.1038/s41467-021-27309-1.
[40]	YANG D, YAO M, YAN Y, et al. Deoxycholic acid upregulates serum Golgi protein 73 through activating NF-κB pathway and destroying golgi structure in liver disease[J]. Biomolecules, 2021, 11(2): 205. DOI: 10.3390/biom11020205.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (536) PDF downloads(97)

Role of serum Golgi protein 73 in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.03.028

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of serum Golgi protein 73 in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.03.028

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content